Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

NCT05947344 is registered in ClinicalTrials.gov with Zhejiang ACEA Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT05947344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
Lead sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 8, 2023
Completion date
December 31, 2025
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult